thalidomide has been researched along with Borderline Lepromatous in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 7.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 5.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 5.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| "Thalidomide is an anti- tumor necrosis factor alpha (TNF-a) drug used mainly in the management of moderate to severe form of Erythema Nodosum Leprosum (ENL)." | 3.96 | Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports. ( Babu, S; Gurunthalingam, M; T, T; Thangaraju, P; Venkatesan, S, 2020) |
| "Thalidomide is an immunomodulatory and anti-inflammatory drug currently used to treat this condition." | 1.72 | Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide. ( Caldoncelli, DIO; Camargo, LMA; Costa, PDSS; Feira, MF; Fraga, LR; Kowalski, TW; Maciel-Fiuza, MF; Schuler-Faccini, L; Silveira, MIDS; Vianna, FSL, 2022) |
| "Apremilast is an orally effective phosphodiesterase-4 inhibitor with a potent immunomodulatory action and is clinically effective in inflammatory conditions like chronic plaque psoriasis." | 1.56 | Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases. ( Dogra, S; Kaushik, A; Narang, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abril-Pérez, C | 1 |
| Palacios-Diaz, RD | 1 |
| Navarro-Mira, MÁ | 1 |
| Botella-Estrada, R | 1 |
| Bathula, S | 1 |
| Sardana, K | 1 |
| Mathachan, SR | 1 |
| Khurana, A | 1 |
| Ahuja, A | 1 |
| Paliwal, P | 1 |
| Costa, PDSS | 3 |
| Maciel-Fiuza, MF | 3 |
| Kowalski, TW | 3 |
| Fraga, LR | 3 |
| Feira, MF | 3 |
| Camargo, LMA | 3 |
| Caldoncelli, DIO | 3 |
| Silveira, MIDS | 3 |
| Schuler-Faccini, L | 3 |
| Vianna, FSL | 3 |
| Ribeiro, SLE | 1 |
| Pereira, HLA | 1 |
| Boechat, AL | 1 |
| Silva, NP | 1 |
| Sato, EI | 1 |
| das Graças Souza Cunha, M | 1 |
| de Souza Passos, LF | 1 |
| Dos-Santos, MC | 1 |
| Thangaraju, P | 1 |
| Venkatesan, S | 1 |
| Gurunthalingam, M | 1 |
| Babu, S | 1 |
| T, T | 1 |
| Sánchez-Martínez, EM | 1 |
| Melgosa-Ramos, FJ | 1 |
| Moneva-Léniz, LM | 1 |
| Gegúndez-Hernández, H | 1 |
| Prats-Máñez, A | 1 |
| Mateu-Puchades, A | 1 |
| Narang, T | 2 |
| Ashraf, R | 1 |
| Kaushik, A | 2 |
| Dogra, S | 2 |
| Zhu, J | 1 |
| Yang, D | 1 |
| Shi, C | 1 |
| Jing, Z | 1 |
| Murthy, V | 1 |
| Horowitz, HW | 1 |
| Pham, VP | 1 |
| Levis, WR | 1 |
10 other studies available for thalidomide and Borderline Lepromatous
| Article | Year |
|---|---|
Successful treatment of erythema nodosum leprosum with apremilast.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Panniculitis; Thalidomide | 2022 |
A real-world study of low-dose thalidomide in severe erythema nodosum leprosum highlighting its mechanistic rationale in a resource-constrained target population.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Pannicu | 2023 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.
Topics: Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalido | 2022 |
Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; beta 2-Glycoprotein I; Enzyme-Link | 2019 |
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Erythema Nodosum; Female; Humans; Infant; Leprosta | 2020 |
Erythema nodosum leprosum successfully treated with apremilast: more effective and safer than classic treatments?
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2021 |
Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Pilot Projects; Prospective | 2021 |
Therapeutic Dilemma of Refractory Erythema Nodosum Leprosum.
Topics: Adrenal Cortex Hormones; Drug Tolerance; Erythema Nodosum; Fatal Outcome; Humans; Immunosuppressive | 2017 |
Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases.
Topics: Erythema Nodosum; Humans; Leprosy, Lepromatous; Leprosy, Multibacillary; Thalidomide | 2020 |
Giant PPD reaction with positive QuantiFERON-TB Gold in a patient with lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Interferon-gamma Release Tests; Latent Tuberculosis; Leprosy, Lepro | 2012 |